GO:0015327 cystine:glutamate antiporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015327 cystine:glutamate antiporter activity is a molecular_function that enables the exchange of cystine and glutamate across a membrane, coupling cystine uptake to glutamate efflux.
• The activity is primarily mediated by the System xc- heterodimer, composed of SLC7A11 (xCT) and SLC3A2 (4F2hc), and is central to cellular redox balance and ferroptosis sensitivity.
• Inhibition or loss of this antiporter triggers endoplasmic reticulum stress and ferroptotic cell death, making it a therapeutic target in cancer and other diseases.
• The antiporter is highly expressed in the central nervous system, where it regulates glutamatergic signaling and synaptic activity.
• Knockout mouse models of the cystine/glutamate antiporter reveal its importance in retinal redox balance and mitochondrial activity.
• Studying GO:0015327 requires tools such as CRISPR knockout, overexpression, and metabolic tracing to dissect its role in health and disease.
Description
The cystine:glutamate antiporter activity (GO:0015327) is a molecular function that mediates the exchange of cystine and glutamate across cellular membranes. This activity is essential for maintaining intracellular cysteine levels, which are required for glutathione synthesis and redox homeostasis. The antiporter is best known as System xc-, a heterodimeric transporter composed of a light chain (SLC7A11) and a heavy chain (SLC3A2). Researchers study this term because it links amino acid transport to ferroptosis, neurodegeneration, and cancer biology. Understanding its regulation and function provides insights into cellular stress responses and potential therapeutic targets.
cystine:glutamate antiporter activity At A Glance
| GO ID | GO:0015327 |
|---|---|
| GO term | cystine:glutamate antiporter activity |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Mediates the exchange of cystine and glutamate across membranes, contributing to redox balance and glutamatergic signaling. |
| Reaction | cystine(out) + glutamate(in) = cystine(in) + glutamate(out) |
| Cellular location | Plasma membrane |
| Key components | SLC7A11 (xCT) and SLC3A2 (4F2hc) |
| Related processes | Ferroptosis, glutathione metabolism, synaptic transmission |
What Is GO:0015327?
According to the Gene Ontology, cystine:glutamate antiporter activity (GO:0015327) enables the transfer of a solute or solutes from one side of a membrane to the other according to the reaction: cystine(out) + glutamate(in) = cystine(in) + glutamate(out). In other words, it is a molecular function that couples the inward transport of cystine with the outward transport of glutamate, typically driven by the concentration gradients of these amino acids.
Why Is cystine:glutamate antiporter activity Important in Cell Biology?
Cystine:glutamate antiporter activity is critical for cellular defense against oxidative stress because it supplies cystine for glutathione synthesis. It also modulates extracellular glutamate levels, influencing neurotransmission and excitotoxicity. Dysregulation of this activity is implicated in cancer, neurodegeneration, and vascular calcification, making it a focal point for therapeutic development.
• Maintains intracellular cysteine and glutathione levels for redox homeostasis.
• Regulates extracellular glutamate, affecting synaptic activity and excitotoxicity.
• Mediates ferroptosis, a form of regulated cell death, in cancer and other diseases.
• Plays a role in tumor suppression via p53-mediated regulation.
• Contributes to vascular calcification through redox imbalance.
• Influences retinal redox balance and mitochondrial activity.
• Serves as a target for pharmacological inhibition to induce ferroptosis in cancer.
• Enables in vivo tracking of cysteine/cystine pools under ferroptosis.
• Involved in normal and pathological glutamatergic signaling.
• Characterized in glial cells, highlighting its role in brain function.
Molecular Mechanism of cystine:glutamate antiporter activity
Substrate Exchange and Transport Cycle
In simple terms: The antiporter swaps cystine from outside the cell with glutamate from inside.
The cystine:glutamate antiporter operates as an obligate exchanger, where the inward transport of cystine is coupled to the outward transport of glutamate. This exchange is driven by the concentration gradients of the substrates and does not require ATP directly. The reaction is reversible depending on the gradients, but under physiological conditions, it typically facilitates cystine uptake and glutamate efflux.
Structural Components: SLC7A11 and SLC3A2
In simple terms: The antiporter is made of two protein subunits that work together.
The functional antiporter is a heterodimer composed of a light chain, SLC7A11 (also known as xCT), which confers substrate specificity, and a heavy chain, SLC3A2 (4F2hc), which is a type II membrane glycoprotein that stabilizes the complex and traffics it to the plasma membrane. SLC7A11 is the catalytic subunit responsible for the transport activity.
Regulation by Cellular Stress and Signaling Pathways
In simple terms: The activity of the antiporter can be turned up or down by cellular signals.
The expression and activity of the cystine:glutamate antiporter are regulated by various stress-responsive transcription factors, including ATF4 and NRF2, which upregulate SLC7A11 under oxidative stress. Conversely, p53 can repress SLC7A11 expression, leading to increased ferroptosis sensitivity. This regulation links the antiporter to tumor suppression and stress responses.
Role in Glutathione Synthesis and Redox Balance
In simple terms: The cystine brought in is used to make an antioxidant.
Once inside the cell, cystine is reduced to cysteine, which is a rate-limiting substrate for glutathione (GSH) synthesis. GSH is a major antioxidant that protects cells from oxidative damage. Therefore, the antiporter activity is essential for maintaining redox homeostasis, and its inhibition leads to GSH depletion and oxidative stress.
Inhibition and Ferroptosis Induction
In simple terms: Blocking the antiporter can cause a type of cell death called ferroptosis.
Pharmacological inhibition of the cystine:glutamate antiporter, for example with erastin or sulfasalazine, induces ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation. This occurs because cystine uptake is blocked, leading to glutathione depletion and loss of GPX4 activity, which normally detoxifies lipid peroxides. Ferroptosis induction is being explored as a therapeutic strategy in cancer.
Key Genes Involved in GO:0015327 cystine:glutamate antiporter activity
The following genes and proteins are key components or regulators of cystine:glutamate antiporter activity (GO:0015327).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A11 | Light chain of the antiporter; mediates substrate transport | Central to ferroptosis and redox biology |
| SLC3A2 | Heavy chain; stabilizes and traffics the antiporter | Essential for functional antiporter complex |
| GPX4 | Glutathione peroxidase; detoxifies lipid peroxides | Downstream of antiporter; ferroptosis regulator |
| GCLC | Glutamate-cysteine ligase catalytic subunit; GSH synthesis | Links antiporter to glutathione production |
| GCLM | Glutamate-cysteine ligase modifier subunit; GSH synthesis | Modulates GSH synthesis capacity |
| GSS | Glutathione synthetase; GSH synthesis | Final step in GSH synthesis |
| GSR | Glutathione reductase; regenerates GSH | Maintains GSH pool |
| NFS1 | Cysteine desulfurase; iron-sulfur cluster biogenesis | May influence ferroptosis sensitivity |
| CBS | Cystathionine beta-synthase; transsulfuration pathway | Alternative cysteine source |
| CTH | Cystathionine gamma-lyase; transsulfuration pathway | Alternative cysteine source |
| ATF4 | Transcription factor; upregulates SLC7A11 under stress | Regulates antiporter expression |
| NRF2 | Transcription factor; upregulates SLC7A11 | Regulates antioxidant response |
| TP53 | Tumor suppressor; represses SLC7A11 | Links antiporter to tumor suppression |
| SLC1A1 | Glutamate transporter; regulates extracellular glutamate | Modulates glutamatergic signaling |
| GRM2 | Metabotropic glutamate receptor; responds to glutamate | Involved in synaptic activity |
| GRM3 | Metabotropic glutamate receptor; responds to glutamate | Involved in synaptic activity |
| SLC7A5 | Amino acid transporter; may interact with SLC3A2 | Potential alternative partner |
How Is cystine:glutamate antiporter activity Regulated?
The activity of the cystine:glutamate antiporter is regulated at multiple levels. Transcriptionally, SLC7A11 is induced by stress-responsive factors such as ATF4 and NRF2 under oxidative stress conditions. Conversely, p53 can repress SLC7A11 expression, promoting ferroptosis. Post-translational modifications and interaction with SLC3A2 are required for proper membrane localization and function. Additionally, the antiporter activity can be modulated by extracellular glutamate levels and redox status.
cystine:glutamate antiporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A11 | Cancer, ferroptosis | CRISPR knockout in cancer cell lines |
| SLC7A11 | Vascular calcification | Knockout in vascular smooth muscle cells |
| SLC7A11 | Neurodegeneration | Conditional knockout in neurons |
| SLC7A11 | Retinal redox imbalance | Knockout mouse model |
| TP53 | Tumor suppression | Point mutation knock-in in cancer models |
Cancer and Ferroptosis
Dysregulation of cystine:glutamate antiporter activity is implicated in cancer. Many cancer cells upregulate SLC7A11 to meet increased antioxidant demands, making them vulnerable to ferroptosis induction by antiporter inhibitors. p53-mediated repression of SLC7A11 contributes to tumor suppression by promoting ferroptosis. Targeting this antiporter is a promising therapeutic strategy for cancers resistant to conventional therapies.
Neurodegeneration and Glutamatergic Signaling
In the central nervous system, the antiporter regulates extracellular glutamate levels, influencing synaptic transmission and excitotoxicity. Dysfunction of the antiporter has been linked to neurodegenerative conditions where glutamate excitotoxicity plays a role. Studies in Bergmann glia highlight its importance in glial-neuronal interactions.
Vascular Calcification
Repression of the SLC7A11/glutathione/GPX4 axis drives ferroptosis of vascular smooth muscle cells, facilitating vascular calcification. This highlights the antiporter's role in cardiovascular pathology and potential as a therapeutic target.
Retinal Redox Balance
Knockout of the cystine/glutamate antiporter in mice leads to changes in redox balance and mitochondrial activity in the retina, suggesting a role in retinal health and disease.
From cystine:glutamate antiporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of SLC7A11 loss on ferroptosis? | CRISPR knockout in cancer cell lines |
| How does SLC7A11 point mutation affect transport activity? | Point mutation knock-in in cell lines |
| Can SLC7A11 overexpression protect against oxidative stress? | Overexpression in neuronal cells |
| What is the role of SLC7A11 in vascular calcification? | Knockout in vascular smooth muscle cells |
| How does SLC7A11 affect retinal function? | Knockout mouse model |
| What is the impact of SLC7A11 on glutamatergic signaling? | Conditional knockout in glial cells |
How to Study the cystine:glutamate antiporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Stable isotope tracing | Cystine/glutamate flux and GSH synthesis | Metabolic studies |
| CRISPR knockout | Loss of antiporter function | Ferroptosis and redox studies |
| Pharmacological inhibition | Acute inhibition of transport | Ferroptosis induction |
| Fluorescent ROS/GSH probes | Oxidative stress and antioxidant levels | Live-cell imaging |
| Western blot | Protein expression of SLC7A11/SLC3A2 | Regulation studies |
| qPCR | mRNA levels of SLC7A11 | Transcriptional regulation |
| Glutamate release assay | Extracellular glutamate levels | Neurotransmission studies |
| Cystine uptake assay | Radiolabeled cystine transport | Transport kinetics |
Metabolic Tracing and Flux Analysis
Stable isotope tracing with labeled cystine or glutamate can measure antiporter activity and downstream glutathione synthesis. This method allows real-time tracking of cysteine/cystine pools under conditions such as ferroptosis induction.
Genetic Knockout and Knockdown
CRISPR-Cas9 knockout or RNA interference of SLC7A11 or SLC3A2 can abolish antiporter activity, enabling studies of its role in ferroptosis, redox balance, and signaling. Knockout models in mice have revealed tissue-specific functions.
Pharmacological Inhibition
Small molecule inhibitors such as erastin and sulfasalazine are commonly used to inhibit the antiporter and induce ferroptosis. These tools help dissect the contribution of the antiporter to cellular phenotypes.
Imaging and Reporter Assays
Fluorescent probes for glutathione or reactive oxygen species (ROS) can indirectly report on antiporter activity. Genetically encoded sensors for glutamate or cystine can provide dynamic measurements in live cells.
How CRISPR Can Be Used to Study GO:0015327 cystine:glutamate antiporter activity
Knockout
CRISPR knockout of SLC7A11 or SLC3A2 completely abolishes cystine:glutamate antiporter activity, leading to glutathione depletion and increased sensitivity to ferroptosis. Knockout cell lines are valuable for studying the antiporter's role in redox homeostasis and cell death.
Point Mutation
Point mutations in SLC7A11 can be introduced to dissect residues critical for substrate binding or transport. Such models help understand the structure-function relationship of the antiporter.
Knock-in
Knock-in of tagged SLC7A11 (e.g., GFP or HA) allows visualization and immunoprecipitation of the antiporter complex, facilitating studies of its localization, interactions, and dynamics.
Overexpression
Overexpression of SLC7A11 increases antiporter activity, enhances glutathione synthesis, and protects cells from oxidative stress and ferroptosis. This model is useful for studying the protective effects of the antiporter in disease contexts.
How EDITGENE Supports cystine:glutamate antiporter activity Research
Researchers studying cystine:glutamate antiporter activity-related genes often need to determine whether a candidate gene is causally involved in transport, redox regulation, or ferroptosis. EDITGENE provides comprehensive CRISPR-based services to create precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for cystine:glutamate antiporter activity research.
Frequently Asked Questions About cystine:glutamate antiporter activity
What is cystine:glutamate antiporter activity?
It is a molecular function (GO:0015327) that exchanges cystine and glutamate across membranes, typically mediating cystine uptake and glutamate efflux.
What genes are involved in cystine:glutamate antiporter activity?
The main genes are SLC7A11 (xCT) and SLC3A2 (4F2hc), which form the System xc- heterodimer.
How is cystine:glutamate antiporter activity regulated?
It is regulated transcriptionally by ATF4, NRF2, and p53, and post-translationally by interaction with SLC3A2.
What diseases are associated with cystine:glutamate antiporter activity?
It is linked to cancer, neurodegeneration, vascular calcification, and retinal disorders.
How can I study cystine:glutamate antiporter activity in the lab?
Common methods include CRISPR knockout, pharmacological inhibition, metabolic tracing, and fluorescent probes.
What is the role of SLC7A11 in ferroptosis?
SLC7A11 is the catalytic subunit of the antiporter; its inhibition leads to glutathione depletion and ferroptosis.
Can cystine:glutamate antiporter activity be measured?
Yes, using radiolabeled cystine uptake assays, glutamate release assays, or genetically encoded sensors.
What are the knockout mouse models for this antiporter?
Knockout mice for SLC7A11 exhibit redox imbalance and mitochondrial changes in the retina.
How does p53 regulate cystine:glutamate antiporter activity?
p53 represses SLC7A11 expression, promoting ferroptosis and tumor suppression.
What CRISPR services are available for studying this antiporter?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services.
Conclusion
Cystine:glutamate antiporter activity (GO:0015327) is a fundamental molecular function that maintains redox balance and modulates glutamatergic signaling. Its dysregulation is implicated in cancer, neurodegeneration, and vascular calcification, making it a prime target for therapeutic intervention. Continued research using advanced CRISPR models and metabolic tracing will further elucidate its roles and therapeutic potential.
References
- 1. Chen X et al.. 2021. Ferroptosis: machinery and regulation.. Autophagy 17(9):2054-2081 PMID: 32804006
- 2. Jiang L et al.. 2015. Ferroptosis as a p53-mediated activity during tumour suppression.. Nature 520(7545):57-62 PMID: 25799988
- 3. Dixon SJ et al.. 2014. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.. Elife 3:e02523 PMID: 24844246
- 4. Bridges R et al.. 2012. Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling.. Pharmacol Rev 64(3):780-802 PMID: 22759795
- 5. Knight LJ et al.. 2025. Changes in Redox Balance and Mitochondrial Activity in the Retinas of Cystine/Glutamate Antiporter Knockout Mice.. Invest Ophthalmol Vis Sci 66(12):31 PMID: 40952056
- 6. Li Z et al.. 2020. In vivo tracking cystine/glutamate antiporter-mediated cysteine/cystine pool under ferroptosis.. Anal Chim Acta 1125:66-75 PMID: 32674782
- 7. Ye Y et al.. 2022. Repression of the antiporter SLC7A11/glutathione/glutathione peroxidase 4 axis drives ferroptosis of vascular smooth muscle cells to facilitate vascular calcification.. Kidney Int 102(6):1259-1275 PMID: 36063875
- 8. Suárez-Pozos E et al.. 2017. Characterization of the cystine/glutamate antiporter in cultured Bergmann glia cells.. Neurochem Int 108:52-59 PMID: 28237844
